Study guide
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know
Key Takeaways Explain This Topic AI
Lung-protective ventilation uses a tidal volume of 6 mL/kg predicted body weight with a plateau pressure of 30 cm H2O or less, ideally with a driving pressure of 15 cm H2O or less.
Predicted body weight comes from height and sex, not actual weight: men 50 + 0.91 × (height in cm − 152.4) kg, and women 45.5 + 0.91 × (height in cm − 152.4) kg.
Noninvasive ventilation has its strongest evidence in hypercapnic COPD exacerbations (pH below 7.35) and cardiogenic pulmonary edema.
A high peak pressure with a normal plateau pressure means high airway resistance, such as bronchospasm, secretions or a kinked tube, rather than stiff lungs.
Aerosol delivery through a ventilator circuit needs the heat-moisture exchanger removed from between the nebulizer and the patient; vibrating mesh nebulizers deliver more drug than jet nebulizers.
Last updated: October 2026
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know
Note
Exam scope: 2025 outline subtopic 1B1 (Mechanical/Assisted Ventilation) within 1B, Medical Therapies and Devices (9% of the exam). Questions test how ventilator settings, oxygen devices and drug delivery interact with pharmacotherapy. Intubation drugs are covered in Chapter 4.
Oxygen Targets
Too much oxygen is not harmless. Hyperoxia causes absorption atelectasis and vasoconstriction, and may worsen outcomes after cardiac arrest and stroke. Common targets:
- Patient group SpO2 target
- Most acutely ill adults About 92 to 96% (some guidelines use 94 to 98%)
- Risk of hypercapnic failure (COPD, obesity hypoventilation, neuromuscular disease) 88 to 92%
- After return of spontaneous circulation 90 to 98% (Section 2.4)
- High-Flow Nasal Cannula (HFNC)
HFNC delivers heated, humidified gas at up to 60 L/min with an FiO2 up to 1.0. It:
Matches the patient's peak inspiratory flow, so the delivered FiO2 is reliable.
Washes CO2 out of the upper airway dead space.
Adds a small amount of positive airway pressure, roughly 1 cm H2O per 10 L/min with the mouth closed.
Is more comfortable than a mask and lets the patient eat, talk and clear secretions.
In the FLORALI trial (2015), HFNC lowered 90-day mortality compared with standard oxygen or noninvasive ventilation in acute hypoxemic respiratory failure without hypercapnia. HFNC is also used for preoxygenation and apneic oxygenation during intubation (Section 4.1).
The ROX index = (SpO2/FiO2) ÷ respiratory rate. A value of 4.88 or higher at 2, 6 or 12 hours predicts HFNC success. Falling values signal the need to escalate.
Noninvasive Positive Pressure Ventilation (NIV)
CPAP gives one continuous pressure. Bilevel (BiPAP) gives a higher inspiratory pressure (IPAP) and a lower expiratory pressure (EPAP). The difference between them is the pressure support that increases tidal volume and removes CO2.
Indication Evidence Typical starting settings
COPD exacerbation with hypercapnic acidosis (pH below 7.35, PaCO2 above 45 mmHg) Strong (ERS/ATS 2017): lowers intubation and mortality IPAP 10 to 12, EPAP 4 to 5 cm H2O, titrated
- Cardiogenic pulmonary edema Strong: CPAP or bilevel reduces intubation CPAP 5 to 10 cm H2O
- Immunocompromised hypoxemic failure, post-extubation in high-risk patients Conditional Individualized
Contraindications: cardiac arrest or impending arrest, inability to protect the airway, uncontrolled vomiting, facial trauma or burns, recent upper GI or airway surgery, severe agitation, and hemodynamic instability.
Reassess blood gases after 1 to 2 hours . A rising PaCO2, falling pH or tiring patient means NIV is failing, and delayed intubation worsens outcomes.
Sedation for NIV Intolerance
Anxiety and mask intolerance are common reasons NIV fails. Choose drugs that preserve respiratory drive:
Dexmedetomidine 0.2 to 0.7 mcg/kg/h, usually without a loading dose to avoid bradycardia and hypotension.
Small opioid doses, such as fentanyl 25 mcg, which can ease air hunger.
Low-dose ketamine. In "delayed sequence intubation," a dissociative dose (about 1 mg/kg) lets a combative hypoxemic patient accept preoxygenation before paralysis.
Avoid repeated benzodiazepine boluses, which depress respiratory drive and worsen hypercapnia.
Invasive Ventilation: Modes and Pressures
Mode Clinician sets Patient-determined Pharmacist relevance
Volume assist-control (most common in the ED) Tidal volume, rate, PEEP, FiO2, flow Airway pressures Peak and plateau pressures reveal resistance or compliance problems
Pressure assist-control Inspiratory pressure, rate, PEEP, FiO2 Tidal volume Tidal volume falls when bronchospasm or stiff lungs develop
Pressure-regulated volume control Target tidal volume Pressure adjusts breath to breath Hides worsening compliance until pressures max out
Pressure support Support pressure, PEEP Rate and volume Spontaneous breathing trials; heavy sedation causes apnea
Reading the Pressures
Pattern Meaning Common causes Typical response
High peak, normal plateau High airway resistance Bronchospasm, secretions, biting or kinked tube Bronchodilators, suctioning, bite block, sedation
High peak and high plateau Low compliance ARDS, pneumothorax, mainstem intubation, abdominal compartment syndrome, auto-PEEP Treat the cause; check breath sounds and imaging
Sudden drop in pressures Leak or disconnection Cuff leak, circuit disconnect, extubation Check the circuit and tube position
Lung-Protective Ventilation
The ARDSNet strategy applies to ARDS and is a sensible default for almost every intubated ED patient:
Tidal volume 6 mL/kg predicted body weight (PBW) , range 4 to 8.
Plateau pressure 30 cm H2O or less.
Driving pressure (plateau minus PEEP) ideally 15 cm H2O or less.
PEEP and FiO2 adjusted together using a table.
PBW depends only on height and sex:
- Men: 50 + 0.91 × (height in cm − 152.4) kg
- Women: 45.5 + 0.91 × (height in cm − 152.4) kg
Worked example: a man 175 cm tall has a PBW of 50 + 0.91 × 22.6 = 50 + 20.6 ≈ 70.6 kg. A tidal volume of 6 mL/kg is about 420 mL , whatever his actual weight. Using actual body weight in an obese patient produces injurious volumes.
A before-and-after ED quality program (LOV-ED, 2017) linked ED-initiated lung-protective ventilation with less ARDS and lower mortality. Early ventilator settings matter even when the patient boards in the ED.
ARDS Adjuncts (ATS 2024 Update)
Prone positioning for at least 12 to 16 hours a day in moderate to severe ARDS (PaO2/FiO2 below 150), based on PROSEVA (2013).
Neuromuscular blockade : suggested for early severe ARDS. The ROSE trial (2019) found no benefit from routine early cisatracurium with deep sedation compared with lighter sedation, so blockade is used selectively for refractory hypoxemia or dyssynchrony.
Corticosteroids : suggested for ARDS in the 2024 ATS guideline.
VV-ECMO : for selected patients with severe ARDS at experienced centers (Section 3.2).
Obstructive Disease on the Ventilator
In severe asthma or COPD, the danger is dynamic hyperinflation (auto-PEEP): the next breath starts before the last one has been exhaled.
Use a low rate (about 10 to 12 breaths/min), tidal volume 6 to 8 mL/kg PBW and a high inspiratory flow to lengthen expiratory time (I:E ratio 1:4 or more).
Accept hypercapnia (permissive hypercapnia) as long as pH stays above about 7.15 to 7.20.
Measure auto-PEEP with an expiratory hold.
If a ventilated asthmatic suddenly becomes hypotensive, disconnect the circuit and let the chest deflate. Then reassess for tension pneumothorax.
Continue in-line bronchodilators, IV magnesium, systemic corticosteroids and, when needed, ketamine as a bronchodilating sedative (Section 7.2).
Inhaled Pulmonary Vasodilators
Inhaled nitric oxide (5 to 20 ppm) and inhaled epoprostenol (about 0.01 to 0.05 mcg/kg/min) dilate vessels only in ventilated lung units. They improve oxygenation and offload a failing right ventricle (massive PE, pulmonary hypertension) but have not reduced mortality in ARDS . Precautions:
Abrupt withdrawal of nitric oxide causes rebound pulmonary hypertension; wean gradually.
Nitric oxide can cause methemoglobinemia and forms nitrogen dioxide.
Epoprostenol's sticky glycine buffer can jam the ventilator's expiratory valve, so the expiratory filter must be changed regularly.
Drug Delivery Through Ventilator Circuits
Device Placement and technique Key points
Metered-dose inhaler with in-line spacer Inspiratory limb near the Y-piece; actuate at the start of inspiration Doses often need to be higher than in spontaneously breathing patients
Jet nebulizer Inspiratory limb, often placed upstream toward the ventilator Adds gas flow that changes delivered tidal volume and triggering
Vibrating mesh nebulizer Inspiratory limb Adds no gas flow and delivers more drug than a jet nebulizer
Important
A heat-moisture exchanger (HME) traps aerosol. Remove it, or use a circuit that bypasses it, during aerosol treatments, and replace it afterward. Place a filter on the expiratory limb to protect the ventilator from drug deposits.
Aerosols can also be given during NIV (nebulizer between the exhalation port and the mask) and through HFNC (vibrating mesh in-line).
Sedation and analgesia for intubated patients follow the "analgesia first, light sedation" approach in Section 4.3. Two ventilator-specific points are worth remembering. Propofol supplies about 1.1 kcal/mL as lipid, so check triglycerides with prolonged infusions. Deep sedation started in the ED tends to carry over into the ICU.